Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2/3 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Sarcoma 1Dermatologic 1Breast 1

Conditions

Skin Neoplasms 1Sarcoma 1Melanoma 1Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × tozuleristide × Clear all
NCT02462629 2023-02-21

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Blaze Bioscience Inc.

Phase 1 Completed
29 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms

NCT02496065 2017-07-13

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Completed
30 enrolled
Breast

Breast Neoplasms

NCT02464332 2016-05-26

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Withdrawn
Sarcoma

Sarcoma

NCT02234297 2016-04-06

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Completed
17 enrolled
CNS

Glioma

NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡